Courtney DiNardo, MD
M.D. Anderson Cancer Center
Emerging Leaders
not ranked
Current Leaders
#1660 pts
All-Time Leaders
#3175 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2013. 12 trials as lead/chair. How it works →
Trials led — by scientific impact
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Phase 2RecruitingM.D. Anderson Cancer Center
15
impact
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
Phase 2RecruitingM.D. Anderson Cancer Center
11
impact
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Phase 2RecruitingM.D. Anderson Cancer Center
11
impact
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Phase 2RecruitingM.D. Anderson Cancer Center
11
impact
Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib
Phase 2RecruitingM.D. Anderson Cancer Center
9
impact
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
Phase 2RecruitingM.D. Anderson Cancer Center
8
impact
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Phase 1RecruitingM.D. Anderson Cancer Center
4
impact
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome
Phase 2CompletedM.D. Anderson Cancer Center
2
impact
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2TerminatedM.D. Anderson Cancer Center
1
impact
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Phase 2RecruitingM.D. Anderson Cancer Center
1
impact
Phase Ib/II Study of Omacetaxine and Venetoclax for Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase 2TerminatedM.D. Anderson Cancer Center
1
impact
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Phase 2ActiveM.D. Anderson Cancer Center
1
impact
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Phase 2RecruitingM.D. Anderson Cancer Center
0
impact
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
Phase 1Not Yet RecruitingM.D. Anderson Cancer Center
0
impact
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Phase 2ActiveM.D. Anderson Cancer Center
0
impact
Evaluating the Effect of a Digital Coaching Program on Self-Efficacy and Patient Reported Outcomes of Individuals With Acute and Chronic Leukemia
N/ACompletedM.D. Anderson Cancer Center
0
impact
Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission
Phase 2TerminatedM.D. Anderson Cancer Center
0
impact
Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes
Phase 2TerminatedM.D. Anderson Cancer Center
0
impact
Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome
Phase 2TerminatedM.D. Anderson Cancer Center
0
impact
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Phase 2CompletedM.D. Anderson Cancer Center
0
impact
Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Phase 2CompletedM.D. Anderson Cancer Center
0
impact